McCarthy Sean A. 4

What Happened

• Sean A. McCarthy, CEO and Director of CytomX Therapeutics (CTMX), was granted equity awards on Feb 2, 2026 totaling 1,190,000 units: 210,000 shares (award code A) and 980,000 derivative awards (code A). Both grants show $0.00 per share at grant (typical for RSUs/compensation awards), so no cash was paid.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (timely within the usual 2-business-day window).
• Price reported: $0.00 per share for both grants (i.e., restricted stock units/awards).
• Total units granted: 210,000 + 980,000 = 1,190,000 awards.
• Shares owned after transaction: not specified in the supplied summary of the filing.
• Footnotes from the filing:
  • F1: These constitute restricted stock units (RSUs); 1/3 of the RSUs vest annually on March 15, with the first vesting on March 15, 2027, subject to continued service.
  • F2: The filing states “Includes 698,750 RSUs” (as reported in the filing).
  • F3: For certain awards, 1/48th vests monthly beginning Feb 2, 2026, with full vesting on the fourth anniversary, subject to continued service.
  • F4: Some shares are held by the Sean A. McCarthy 2018 Trust, of which he is trustee.
• Filing status: timely (no late filing flag reported).

Context

• These awards appear to be time-based compensation (RSUs and/or time-vesting derivative awards) that convert into common stock only upon vesting; no shares were sold or purchased in this filing. Such grants are common executive compensation and reflect future vesting tied to continued service rather than an immediate market trade.